Press Releases

Date	Title and Summary	Additional Formats
Toggle Summary May 2, 2018	Harvard Bioscience Reports First Quarter 2018 Financial Results -Reports GAAP and adjusted non-GAAP revenue of $26.8 million and $27.7 million , respectively, an increase of 48% and 15%, respectively- HOLLISTON, Mass. , May 02, 2018 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq:HBIO), or the Company, a global developer, manufacturer and marketer of a	View HTML PDF Version
Toggle Summary May 1, 2018	Harvard Bioscience Subsidiary Multi Channel Systems Launches Beta Cell Screening System for Diabetes Research, Entering New Segment of Electrophysiology Market Multi-Electrode Array (MEA) Offers New Route for Type 2 Diabetes Drug Development and Ability to Elucidate Beta Cell Pathophysiology HOLLISTON, Mass. , May 01, 2018 (GLOBE NEWSWIRE) -- Multi Channel Systems (MCS), a subsidiary of Harvard Bioscience, Inc.	View HTML PDF Version
Toggle Summary May 1, 2018	Harvard Bioscience Subsidiary Data Sciences International Launches Two Telemetry Implants to Enhance Neuroscience Research PhysioTel™ Digital L03 and L04 Designed to Improve Animal Welfare in Large Animal Models ST. PAUL, Minn. and HOLLISTON, Mass. , May 01, 2018 (GLOBE NEWSWIRE) -- Data Sciences International (DSI), a subsidiary of Harvard Bioscience, Inc. (Nasdaq:HBIO) and the global leader in wireless physiologic	View HTML PDF Version
Toggle Summary Apr 23, 2018	Harvard Bioscience Schedules First Quarter 2018 Conference Call for May 2 at 4:30 PM ET HOLLISTON, Mass. , April 23, 2018 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, will announce results for its first quarter 2018 after market trading hours on Wednesday, May 2, 2018 .	View HTML PDF Version
Toggle Summary Mar 1, 2018	Harvard Bioscience Reports Fourth Quarter and Year-End 2017 Results Third Consecutive Quarter of Top Line Organic Growth and DSI Acquisition Position Company for Further Improvements in 2018	View HTML Harvard Bioscience Reports Fourth Quarter and Year-End 2017 Results 70.1 KB
Toggle Summary Feb 22, 2018	Harvard Bioscience Schedules Fourth Quarter 2017 Conference Call for March 1 at 4:30 PM ET HOLLISTON, Mass., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, will announce results for its fourth quarter 2017 after market trading hours on Thursday, March 1, 2018.	View HTML Harvard Bioscience Schedules Fourth Quarter 2017 Conference Call for March 1 at 4:30 PM ET 13.5 KB
Toggle Summary Jan 31, 2018	Harvard Bioscience Completes Acquisition of Data Sciences International HOLLISTON, Mass., Jan. 31, 2018 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq:HBIO) (the "Company"), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, announced today that the Company has completed the previously announced acquisition of	View HTML Harvard Bioscience Completes Acquisition of Data Sciences International 11.9 KB
Toggle Summary Jan 22, 2018	Harvard Bioscience To Acquire Data Sciences International and Sells Denville Scientific Reports 2018 Guidance -Conference Call and Webcast Scheduled for Tuesday, January 23 at 7:30 AM ET- HOLLISTON, Mass., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq:HBIO) (the "Company"), a global developer, manufacturer and marketer of a broad range of solutions to advance	View HTML Harvard Bioscience To Acquire Data Sciences International and Sells Denville Scientific 32.1 KB
Toggle Summary Oct 26, 2017	Harvard Bioscience Reports Third Quarter 2017 Financial Results HOLLISTON, Mass., Oct. 26, 2017 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq:HBIO) (the "Company"), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, reported financial results for the three and nine months ended September 30, 2017.	View HTML Harvard Bioscience Reports Third Quarter 2017 Financial Results 67.7 KB
Toggle Summary Oct 25, 2017	Harvard Bioscience Appoints Katherine Eade and Thomas Loewald to the Board of Directors HOLLISTON, Mass., Oct. 25, 2017 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq:HBIO) (the "Company"), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, appointed Katherine Eade and Thomas Loewald as Class II directors of the Board of	View HTML Harvard Bioscience Appoints Katherine Eade and Thomas Loewald to the Board of Directors 13.1 KB